Sign in Subscribe
Biotechnology industries

Immusol Appoints Nicholas F. Paoni, Ph.D. as Vice President of Therapeutics

Strategic Insights

— 1 min read

Immusol, a San Diego-based biopharmaceutical company, has announced the appointment of Nicholas F. Paoni, Ph.D. as its new Vice President of Therapeutics. Dr. Paoni will lead the development of the company's protein therapeutic and small molecule-based drug programs. With a background in chemistry and biochemistry, Dr. Paoni has extensive experience in drug development, having previously worked at Genentech, Inc. for nearly 20 years, where he contributed to the research and development of two commercial products, Activase(R) and TNKase(TM). His expertise will be a significant asset to Immusol's organization.

Key Takeaways:

  • Immusol has appointed Nicholas F. Paoni, Ph.D. as its new Vice President of Therapeutics.
  • Dr. Paoni will lead the development of the company's protein therapeutic and small molecule-based drug programs.
  • He has over 20 years of experience in drug development, including stints at Genentech, Inc. and the University of Notre Dame.
  • Dr. Paoni's experience in developing two commercial products, Activase(R) and TNKase(TM), positions him as a valuable asset to Immusol's organization.
  • He will work closely with Immusol's Chief Scientific Officer and Executive Vice President of Research, Dr. Flossie Wong-Staal.
  • Dr. Paoni holds a Bachelor of Science degree in biochemistry from the University of California, Davis and a doctorate in chemistry with an emphasis in biochemistry from the University of Notre Dame.
  • Immusol is a privately-held biopharmaceutical company engaged in the discovery and development of novel therapies to treat human diseases.
  • The company uses an integrated biology approach to discover therapeutic proteins and targets in various disease areas, including cancer, viral infections, ophthalmology, and neurodegenerative and metabolic diseases.
  • Immusol has several lead drug candidates in various stages of clinical and pre-clinical development.

Statistics:

  • 20 years: Dr. Paoni's tenure at Genentech, Inc.
  • 2: Number of commercial products Dr. Paoni contributed to research and development, including Activase(R) and TNKase(TM).
  • 2: Number of research centers Dr. Paoni was appointed to at the University of Notre Dame, the W.M. Keck Center for Transgene Research and the Walther Cancer Research Center.

Sources:

  • PRNewswire
  • Immusol

Read more